HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
CGP 39551
N-methyl-D-aspartate receptor antagonist; structure given in first source
Also Known As:
2-amino-4-methyl-5-phosphono-3 pentenoic acid carboxyethyl ester; CGP-39551; 3-Pentenoic acid, 2-amino-4-methyl-5-phosphono-, 1-ethyl ester, (E)-(+-)-
Networked:
20
relevant articles (
1
outcomes,
0
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Amino Acids, Peptides, and Proteins: 1
Amino Acids: 30675
Branched-Chain Amino Acids: 2289
Valine: 1999
2-Amino-5-phosphonovalerate: 94
CGP 39551: 20
Phosphoamino Acids: 1
2-Amino-5-phosphonovalerate: 94
CGP 39551: 20
Related Diseases
1.
High Pressure Neurological Syndrome (High Pressure Nervous Syndrome)
09/17/1993 - "
It is concluded that CGP 39551 may play an important role in the prophylactic treatment of HPNS.
"
09/17/1993 - "
CGP 39551 significantly ameliorated the signs of HPNS, compared with controls, at pressures above 31 ATA and prevented the severe signs from occurring at the higher pressures.
"
09/17/1993 - "
The orally active NMDA receptor antagonist CGP 39551 ameliorates the high pressure neurological syndrome in Papio anubis.
"
09/17/1993 - "
The neurophysiological effects of a novel, orally active, competitive N-methyl-D-aspartate (NMDA) receptor antagonist (DL-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester), CGP 39551, on the high pressure neurological syndrome (HPNS) were investigated in the non-human primate Papio anubis.
"
2.
Seizures (Absence Seizure)
09/23/1996 - "
Similarly, 2 and 4 weeks after repeated treatment CGP 39551 (15 and 30 mumol kg-1) the ED50 values against clonic and tonic seizures were not significantly different from those observed following an acute administration.
"
09/23/1996 - "
Similarly, CGP 39551 attenuated the clonic and tonic phases of audiogenic seizures 120 min after acute treatment with ED50 values of 17.2 and 8.8 mumol kg-1, respectively.
"
03/01/1997 - "
In adult rats, all doses of CGP 39551 blocked generalized tonic-clonic pentylenetetrazol-induced seizures.
"
05/14/1992 - "
Following oral treatment, the duration of action of CPPene was about 8 h, while CGP 39551 still protected against audiogenic seizures after 16 h.
"
04/22/1992 - "
These results suggest that CGP 37849 and CGP 39551 may be of limited therapeutic usefulness against complex partial seizures in man, the seizure type showing greatest refractoriness to presently available medication.
"
3.
Catalepsy
07/01/1993 - "
After CGP 39551 administration, a decreased muscle tension was observed, which rendered evaluation of the influence on catalepsy impossible.
"
01/01/1993 - "
CGP 37849 antagonized the spiperone- and fluphenazine-induced catalepsy; CGP 39551 had considerably weaker antagonistic effect.
"
01/01/1992 - "
The effects of competitive (CGP 37849 and CGP 39551) and non-competitive (dizocilpine) N-methyl-D-aspartate (NMDA) antagonists were tested in three animal models (catalepsy, sniffing, locomotion) and, in addition, the modulation of these effects by an agonist of the strychnine-insensitive glycine binding site was investigated.
"
06/01/1991 - "
The results show that the non-competitive NMDA antagonists dizocilpine and memantine as well as the competitive antagonists CGP 39551, CGP 37849 and CPPene antagonized dopamine D2 receptor mediated catalepsy induced by haloperidol.
"
4.
Epilepsy (Aura)
09/23/1996 - "
Lack of development of tolerance to anticonvulsant effects of two excitatory amino acid antagonists, CGP [corrected] 37849 and CGP 39551 in genetically epilepsy-prone rats.
"
02/14/1995 - "
This result suggests a wider therapeutic range for CGP 39551 and especially for CGP 37849 than for MK-801 in the treatment of epilepsy.
"
02/01/1991 - "
Anticonvulsant and behavioral effects of two novel competitive N-methyl-D-aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy.
"
09/23/1996 - "
Two selective excitatory amino acid antagonists, DL-(E)-2-amino-4-methyl- 5-phosphono-3-pentenoic acid (CGP 37849) and its carboxyethylester (CGP 39551), were studied against audiogenic seizures in genetically epilepsy-prone rats following oral administration.
"
5.
Myoclonus (Nocturnal Myoclonus)
07/01/1991 - "
Anticonvulsant activity of two orally active competitive N-methyl-D-aspartate antagonists, CGP 37849 and CGP 39551, against sound-induced seizures in DBA/2 mice and photically induced myoclonus in Papio papio.
"
Related Drugs and Biologics
1.
N-Methyl-D-Aspartate Receptors (NMDA Receptors)
2.
2-amino-4-methyl-5-phosphono-3-pentenoic acid
3.
N-Methylaspartate (NMDA)
4.
Dizocilpine Maleate (Dizocilpine)
5.
Anticonvulsants (Antiepileptic Drugs)
6.
Acids
7.
SDZ EAA 494 (cppene)
8.
Excitatory Amino Acid Antagonists
9.
Dopamine D2 Receptors (Dopamine D2 Receptor)
10.
Strychnine
Related Therapies and Procedures
1.
Injections
2.
Oral Administration